Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
15.324 / 17.026
#122586

Re: Farmas USA

SP
+1,2
Día clave hoy.
Un cierre con fortaleza daría mucha tranquilidad. Lo contrario, en todos los sentidos.




Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.

#122587

Re: Farmas USA

KPTI 

No. Tienes que ir al F4 a verlo. Si te fijas, adquiere las mismas que vende, aunque a veces el retail se ve influido por esos posts tendenciosos. 

https://insideri.com/1503802_000120919120035949_0001209191-20-035949

KPTI refleja el IBB, y ayer la hostia fue poca.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#122588

Re: Farmas USA

Y normalmente los F4 son programados y siguen esa estructura, donde entran unas regaladas y se venden otras a precio de mercado para que el CEO en cuestión realice su sueldo.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#122589

Re: Farmas USA

KPTI

Ahm, estupendo! Apuntado queda. Muchas gracias, una vez más! Vi la información, que puse en varios sitios, y la di por buena. Entonces, "paja" una vez más.
Siento la mala información y no haberla contrastado correctamente. A ver si hoy remontan, que parece que va a estar todo mejor que ayer y nos dan una alegría al cierre de la semana. Buen día!
#122590

Re: Farmas USA

KPTI

Presentaciones 11-21 de junio en la asociación europea de hematología.


Karyopharm Therapeutics Inc. (NASDAQ:KPTI), an innovation-driven  pharmaceutical company, today announced that eight posters relating to XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and eltanexor, its next generation SINE compound, will be presented at the European Hematology Association (EHA) 2020 Virtual Annual Meeting taking place June 11-21, 2020.




The six selinexor abstracts include: (i) overall survival data from the Phase 2b SADAL study evaluating selinexor in patients with relapsed or refractory diffuse large-B-cell lymphoma (DLBCL) demonstrating a 9-month median overall survival in a patient population in which survival is expected to be <6 months based on several historical controls, with the median overall survival not yet reached in the 29% of patients who had partial or complete responses on single agent selinexor; (ii) a post-hoc analysis from the SADAL study demonstrating clinically meaningful response rates in the subgroup of patients with primary refractory DLBCL and treated with at least two prior regimens; (iii) a post-hoc analysis from the SADAL study demonstrating durable response rates regardless of the number of prior lines of therapy or prior treatment with high dose chemotherapy with autologous stem cell transplant; (iv) an assessment of molecular markers that may predict response to selinexor in patients with DLBCL; (v) data demonstrating the anti-myeloma effects of selinexor in combination with eukaryotic translation initiation factor 4E (eIF4E); and (vi) data demonstrating selinexor’s potential to treat patients with acute myeloid leukemia harboring IDH2 pR172K mutations.




The two eltanexor abstracts include: (i) data demonstrating the efficacy of eltanexor in preclinical models of NPM1-mutated acute myeloid leukemia; and (ii) an assessment of molecular markers that may predict a response to eltanexor in patients with relapsed or refractory multiple myeloma.




“The Phase 2b SADAL study in patients with heavily pretreated DLBCL continues to generate encouraging efficacy and safety data from multiple datasets and post-hoc analyses, including a superior survival benefit over what has historically been observed with other therapies,” said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm.  “As we await the decision from the U.S. Food and Drug Administration on our supplemental new drug application expected later this month, our sales force is actively preparing for the potential launch of XPOVIO in the additional indication of relapsed or refractory DLBCL. The SADAL data presented at EHA this year will be an important component of our physician education effort surrounding XPOVIO to treat patients with DLBCL, if approved.”




Details for the EHA 2020 virtual poster presentations are as follows:




Selinexor




Title:
Survival Among Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Single Agent Selinexor in the SADAL Study

Lead author: Marie Maerevoet, Institut Jules Bordet

Abstract #: EP1260

Session: 19. Aggressive Non-Hodgkin Lymphoma – Clinical




Title:
Efficacy and Safety of Single Agent Oral Selinexor in Patients with Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the SADAL Study

Lead author: Josee Zijlstra, Amsterdam Universitair Medische Centra, Vrije Universiteit, Cancer Center

Abstract #: EP1226

Session: 19. Aggressive Non-Hodgkin lymphoma – Clinical




Title:
Effect of Prior Therapy on the Efficacy and Safety Of Oral Selinexor in Patients With Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Lead author: George Follows, Addenbrooke’s Hospital, Cambridge, United Kingdom

Abstract #: EP1244

Session: 19. Aggressive Non-Hodgkin lymphoma - Clinical




Title:
Combined Inhibition of XPO1 and eIF4E Prevents Protein Translation resulting in Synergistic Anti-Myeloma Effects

Lead author: Shirong Li, Columbia University

Abstract #: EP1910

Session: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research




Title:
IDH2 p.R172K Mutations in Patients with Acute Myeloid Leukemia (AML) May Be Associated with Favorable Response to Selinexor Treatment

Lead author: Christopher Walker, Karyopharm Therapeutics Inc.

Abstract #: EP484

Session: 03. Acute myeloid leukemia - Biology & Translational Research




Title:
Comprehensive Assessment of Molecular Markers of Selinexor Response in Patients with Diffuse Large B-cell Lymphoma (DLBCL)

Lead author: Christopher Walker, Karyopharm Therapeutics Inc.

Abstract #: EP1328

Session: 20. Lymphoma Biology & Translational Research




Eltanexor




Title:
Continuous XPO1 Inhibition with Eltanexor is Highly Effective in NPM1-mutated AML In Vivo

Lead author: Giulia Pianigiani, University of Perugia

Abstract #: EP441

Session: 03. Acute myeloid leukemia - Biology & Translational Research




Title:
RNA and DNA Sequencing Reveal Markers of Response to the XPO1 Inhibitor Eltanexor in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Lead author: Christopher Walker, Karyopharm Therapeutics Inc.

Abstract #: EP890

Session: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#122591

Re: Farmas USA

Amrn

Buena pre de momento